INTRODUCTION
============

Primary bone lymphoma (PBL) is rare cancer that accounts for 5% of non-Hodgkin's lymphomas (NHL) and 3% of all malignant bone diseases.[@B1] Most studies feature the same epidemiological characteristics, such as predominance in males, initial symptoms of the disease, diagnosis in the 5th and 6th decades of life, and relatively favorable survival prognosis.[@B1] ^-^ [@B4] Even so, there is no consensus on best management because of the limited number of patients reported in the case series. There is also little agreement about treatment options and their results. The method of diagnosis often varies; more precise diagnosis allows better treatment choices. Streamlined staging has helped reduce the number of patients with PBL, excluding cases with evidence of systemic disease during the first six months of diagnosis.[@B5] Treatment has been evolving since 1960, when radiation therapy was the method of choice, yielding high rates of local control of the disease but also high levels of systemic failure.[@B6] ^-^ [@B8] Evidence of considerable increases in survival rates after adding chemotherapy to PBL treatment are frequent in the literature. Currently, treatment includes a combination of chemotherapy and radiation versus the traditional radiation alone.^4.9^ In the late 1990s, rituximab, a monoclonal anti-CD20 antibody, was added to chemotherapy and became the standard treatment for B-cell lymphomas. After rituximab was used for treatment, survival improved significantly for diffuse large B-cell lymphoma (DLBCL). Even so, the role of this drug in treating PBL is not yet clear because of the limited number of patients with this diagnosis. It is difficult to evaluate the benefits of rituximab in treating this disease because of its favorable prognosis for survival. An initial experience treating PBL in our service was published in 2002.[@B10] At that time, our patients did not receive rituximab.[@B10] We therefore resolved to review the cases of PBL diagnosed at our institution after 2002, to analyze how changes in diagnosis and treatment currently impact patients.

MATERIALS AND METHODS
=====================

The study was approved by the HCFMUSP institutional review board (process 11313). This cross-sectional retrospective study utilized records from 55 patients diagnosed with PBL by the Orthopedic Oncology Group at IOT-HC-FMUSP from 2000 to 2016. Thirteen of the medical records were excluded due to lack of information, and 42 were included in the study. All the patients were diagnosed with PBL and received primary treatment. Age, sex, clinical stage (in accordance with the Ann Arbor system), serum lactic dehydrogenase level (LDH), presence of B symptoms, and IPI[@B11] were acquired from the medical records. The histological diagnosis was performed or reviewed by pathologists from our institute, and the patients were classified according to the World Health Organization (WHO) classification for hematopoietic and lymphatic tissue tumors.[@B12] Immunophenotype was identified with a immunohistochemical panel on paraffin-embedded tissue, using the following antibodies: BCL-2, BCL-6, CD3, CD5, CD10, CD15, CD20, CD30, CD45, CD79, and Ki-67. All patients received at least two cycles of rituximab to be considered for the medication use group. The clinical and demographic characteristics were described according to the following measures: average, standard deviation, median, minimum and maximum for quantitative variables, and absolutes and relatives for the qualitative variables.[@B13] The average survival time estimated was according to characteristic using the Kaplan-Meier method.[@B14] It was not possible to estimate the average survival for the entire cohort because the number of deaths was lower than 50%. Survival was compared between the categories using the log-rank test.[@B14] The risk rate was estimated retrospectively (CI=95%) with bivariate Cox regression. The multiple Cox model was estimated using the variables that showed a descriptive level less than 0.2 (p\<0.2), and only the variables with statistical significance remained in the final analysis. All tests were performed at a 5% significance level. The data were analyzed using Statistical Package for the Social Sciences software. This review follows our 2002 publication,[@B10] and describes clinical and histological presentation, treatment, and results.

RESULTS
=======

Most patients were men (61.9%), median age at diagnosis was 51.5 years, and median follow up was 102.7 months (from 4 to 114 months). One patient was HIV positive (2.4%). One patient had B symptoms (2.4%). Pain in the affected limb was the most prevalent symptom (100%). The average time between the appearance of symptoms and diagnosis was 5.4 months. The most affected areas were the vertebrae (n=16, 33.3%), the femur (n=12, 23.8%), and the tibia (n=4, 9.5%). LDH was elevated in 13 patients (30.9%). Eleven patients (26.2%) had pathological fracture at diagnosis. Twenty-three percent of patients were surgically treated, and arthrodesis was most commonly performed. Using the International Prognosis Index Score (IPI), 64.3% of patients were low grade and 25.7% were low-intermediate. The most common histological diagnosis was DLBCL, affecting 85.7% of patients. Immunophenotyping was performed in all cases, and 95.3% were CD20 positive. ([Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}) All patients received chemotherapy, isolated, or in association with rituximab, and 38.1% of cases also received radiation therapy. Cases of pathologic fracture, imminent fracture, or medullary compression were treated surgically. Only two cases with pathological fracture did not receive surgical treatment. ([Figures 1](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"}) The total percentage of survival was 50% and average survival was 80 months. The risk of death increased by 4% for each year of the patient's age. Age and chemotherapy regimen together had a direct influence on patient survival. Young patients as well as those who received R-CHOP had a better prognosis for survival. It was not possible to estimate the average time for the entire cohort because the number of deaths was lower than 50%. ([Figures 3](#f3){ref-type="fig"} and [4](#f4){ref-type="fig"})

Table 1Population distribution according to characteristic.VariableDescription (N=42)Sex, n (%)Female16(38.1)Male26(61.9)**Age (years)**Mean (SD)49.4(18.4)Median (min-max)51.5(11-77)**Location, n (%)**Vertebra14(33.3)Femur10(23.8)Tibia4(9.5)Ilium3(7.1)Humerus3(7.1)Other8(19.0)**Clinical presentation n (%)**Pain in affected site42(100.0)Fever1(2.4)**Duration of symptoms (months)**Mean (SD)5.27Median (min-max)21 to 36**LHD**Mean (SD)834.9954.3Median (min-max)549.5168-593.4**Pathological Fracture**No3173.8Yes1126.2**Histology**DLBCL3788Diffuse small-cell lymphoma24.8Diffuse small-cell and large B-cell lymphoma24.8T-cell lymphoma12.4**IPI**Low2764.3Low-intermediate1545.7

Table 2Average survival according to data from comparative tests.CI95%CI95%VariableMean ValueBelowAboveRRBelowAboveDeathsTotal%time (months)Age(\<) / (=) Median732.0480.9983.11.0061931.6(\>) Median205.900.0446.72.260.875.88152365.2SexFemale552.2282.6821.81.0081650.0Male408.5144.2672.91.000.412.40132650.0Symptom duration(\<) / (=) Median229.800.0491.71.00152365.2(\>) Median748.3507.4989.30.440.171.1461931.6HIVNo425.9208.6643.11.00214151.2Yes155.0155.0155.00.050.00538.750100.0LHDNormal453.0133.8772.21.0081747.1Abnormal461.6214.0709.30.850.352.07132552.0LocationTrunk545.0284.0805.91.0091947.4Limbs444.2190.3698.10.910.382.18122352.2Pathological FractureNo490.0238.0741.91.00143145.2Yes83.735.3132.01.460.593.6371163.6ImmunophenotypingCD371.555.687.41.001250.0CD2068.241.395.01.840.2414.24132259.1Both680.7429.3932.11.030.138.4471838.9IPILow452.0204.1700.01.00132748.1Low-Intermediate505.4216.5794.21.290.533.1381553.3Radiation therapyNo375.2134.0616.51.00152657.5Yes681.4415.6947.20.740.281.9161637.5ChemotherapyCHOP80.650.5110.71.00182864.3R-CHOP824.0541.01107.10.310.091.0631421.4Total455.8249.2662.5214250.0

Figure 1X-ray image of a primary bone lymphoma in the proximal tibia (prior to chemotherapy).

Figure 2X-ray image of a primary bone lymphoma in the proximal tibia (after chemotherapy).

Figure 3Average survival, according to age at diagnosis.

Figure 4Average survival, according to chemotherapy regimen.

DISCUSSION
==========

The medical literature does not feature an extensive volume of publications on PBL, mainly because of the rarity of this disease. Most of the lymphoma cases actually presented extra-osseous disease. Therefore, most of the published studies are retrospective series. The present study was no exception; we analyzed 55 consecutive cases over 15 years, 13 of which were excluded due to lack of complete information in the medical records. In our previous study from 2002,[@B10] 57 of the 81 cases were excluded due to lack of data in the patient chart. Comparatively, in the larger published series, we found one study involving 119 cases over 38 years, and in another 82 cases over 40 years.[@B15] ^,^ [@B16] This makes the present study the largest series reported in Latin America. We also observed that our service had twice the number of cases of the other studies in half the time, which reflects improvement in the ability to diagnose patients with PBL. The average amount of time from appearance of symptoms to date of diagnosis was 5.4 months, similar to the data reported in other studies.[@B16] This also shows the improved access to public health that residents in some areas of Brazil currently enjoy. However, and particularly in our study, time of diagnosis did not affect the prognosis of patients with PBL. As expected, the epidemiological characteristics of PBL were found in our series: the median age was in the fifties and sixties, men were more prevalent, and pain was the main symptom. An important difference from the literature is that the most frequently affected site was the vertebrae, as we also found in our previous publication.[@B10] Other studies generally show that the femur is most frequently affected.[@B15] ^,^ [@B16] Few prognostic factors were found in the statistical analysis. In our study, age appears to be a prognostic factor, which is compatible with the literature;[@B4] ^,^ [@B16] younger patients had a more favorable prognosis for survival. There is no consensus on the significance of the prognosis and location of disease involvement (axial or appendicular). We also did not find a statistically significant difference in site affected in relation to survival prognosis in our series.[@B3] ^,^ [@B10] ^,^ [@B17] The IPI scale is not used universally for reporting PBL, but in our study we found that most patients were classified as low grade, which is similar to the findings of publications that use this same scale.[@B15] The fact that the majority of publications do not use the IPI shows that this scale does not play a definitive role in the prognosis for PBL. In terms of treatment, chemotherapy is always used to treat PBL, even when the disease is localized.[@B5] ^,^ [@B16] We also found that rituximab, a monoclonal antibody directed against B-cell marker CD20, which is expressed in NHL, has been used to treat bone lymphoma since 1997.[@B17] ^,^ [@B18] However, this medication has only been approved for use in the Brazilian public health system since 2012. Consequently, only 13 patients (30%) in our series received this medication, which may have had a negative impact on survival prognosis in our cases. In the present study, lower age as well as the use of rituximab were significantly associated with better survival prognosis in patients with PBL. Because it is a rare disease, compilation of a large number of PBL cases is a lengthy process, which leads to a bias in relation to the diagnosis and treatment of this disease, in turn compromising analysis of the prognosis in the patients studied. In comparison with our previous study,[@B10] we observed significant differences in relation to current diagnosis and treatment of PBL. For example, in the previous study fewer than 80% of the patients received chemotherapy as part of their treatment; in our current study, 100% of patients were treated with chemotherapy. We can conclude that chemotherapy should continue to be used in all cases of PBL, with the addition of radiotherapy and surgery in specific situations. We should also mention that immunotherapy with rituximab should be part of chemotherapy treatment for a better survival prognosis in patients affected by this disease.

CONCLUSION
==========

The use of rituximab in the treatment regimen and lower patient age were associated with better survival prognosis in patients with PBL.
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